<p>abrdn Life Sciences Investors（紐約證券交易所代碼：HQL - 獲取免費報告）的股票在週三的午盤交易中創下了 52 周的新高。該公司的股票最高交易價格為 18.10 美元，最後交易價格為 18.1250 美元，交易量為 68327 股。該股票之前的收盤價為 17.90 美元。</p>
<h2>abrdn Life Sciences Investors 上漲 1.7%</h2>
<p>該公司的 50 日移動平均價格為 16.88 美元，200 日移動平均價格為 16.93 美元。</p>
<h2>abrdn Life Sciences Investors 增加股息</h2>
<p>該公司最近還宣佈了一項季度股息，該股息於 3 月 31 日（星期二）支付。2 月 20 日（星期五）登記在冊的股東獲得了每股 0.56 美元的股息。這代表着每年 2.24 美元的股息和 12.3% 的收益率。該股息的除息日期為 2 月 20 日（星期五）。這比 abrdn Life Sciences Investors 之前的季度股息 0.50 美元有所增加。</p>
<h2>abrdn Life Sciences Investors 的機構交易</h2>
<p>一些機構投資者最近對 HQL 的持倉進行了調整。KPP Advisory Services LLC 在第一季度將其在 abrdn Life Sciences Investors 的股份增加了 5.8%。KPP Advisory Services LLC 現在擁有該公司 24,591 股股票，價值 40 萬美元，此前在此期間又購買了 1,354 股。Geneos Wealth Management Inc.在第二季度將其在 abrdn Life Sciences Investors 的持倉增加了 200.1%。Geneos Wealth Management Inc.現在擁有該公司 2,293 股股票，價值 29,000 美元，此前在此期間又購買了 1,529 股。NewEdge Advisors LLC 在第二季度將其在 abrdn Life Sciences Investors 的股份增加了 5.2%。NewEdge Advisors LLC 現在擁有該公司 34,190 股股票，價值 438,000 美元，此前在上個季度又購買了 1,690 股。Uhlmann Price Securities LLC 在第一季度將其在 abrdn Life Sciences Investors 的股份增加了 2.3%。Uhlmann Price Securities LLC 現在擁有該公司 77,857 股股票，價值 1,267,000 美元，此前在上個季度又購買了 1,719 股。最後，Blue Bell Private Wealth Management LLC 在第三季度將其在 abrdn Life Sciences Investors 的持倉增加了 2.9%。Blue Bell Private Wealth Management LLC 現在擁有該公司 64,828 股股票，價值 1,005,000 美元，此前在此期間又購買了 1,800 股。32.21% 的股票由機構投資者和對沖基金持有。</p>
<h2>abrdn Life Sciences Investors 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>abrdn Life Sciences Investors NYSE: HQL 是一家封閉式管理投資公司，旨在通過投資生命科學領域實現資本增值。該信託成立於 1994 年，專注於從事生物技術、製藥、醫療設備、診斷及相關領域的公司的股票及相關證券。其封閉式結構使投資組合經理能夠維持穩定的資本池，追求長期投資策略，並在適當時使用槓桿。</p>
<p>該基金的投資組合涵蓋了公共和私人公司，重點關注推動藥物開發、基因治療、精準醫療和醫療技術創新的企業。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 abrdn Life Sciences Investors</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 abrdn Life Sciences Investors 嗎？</h2>
<p>在考慮 abrdn Life Sciences Investors 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 abrdn Life Sciences Investors 並不在名單上。</p>
<p>雖然 abrdn Life Sciences Investors 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>abrdn Life Sciences Investors（紐約證券交易所代碼：HQL）的股票達到了新的 52 周高點 18.10 美元，收盤價為 18.1250 美元，交易量為 68,327 股。該股票上漲了 1.7%，50 日移動平均價為 16.88 美元。公司最近將季度股息提高至每股 0.56 美元，收益率為 12.3%。機構投資者增加了持股比例，目前 32.21% 的股票由此類實體持有。該公司專注於生命科學領域的投資，包括生物技術和製藥</p>

<p>Shares of abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $18.10 and last traded at $18.1250, with a volume of 68327 shares traded. The stock had previously closed at $17.90.</p>
<div class="lb-trans"><p>abrdn Life Sciences Investors（紐約證券交易所代碼：HQL - 獲取免費報告）的股票在週三的午盤交易中創下了 52 周的新高。該公司的股票最高交易價格為 18.10 美元，最後交易價格為 18.1250 美元，交易量為 68327 股。該股票之前的收盤價為 17.90 美元。</p>
</div><h2>abrdn Life Sciences Investors Trading Up 1.7%</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 上漲 1.7%</h2>
</div><p>The business has a fifty day moving average price of $16.88 and a 200 day moving average price of $16.93.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 16.88 美元，200 日移動平均價格為 16.93 美元。</p>
</div><h2>abrdn Life Sciences Investors Increases Dividend</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th were paid a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 12.3%. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from abrdn Life Sciences Investors's previous quarterly dividend of $0.50.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，該股息於 3 月 31 日（星期二）支付。2 月 20 日（星期五）登記在冊的股東獲得了每股 0.56 美元的股息。這代表着每年 2.24 美元的股息和 12.3% 的收益率。該股息的除息日期為 2 月 20 日（星期五）。這比 abrdn Life Sciences Investors 之前的季度股息 0.50 美元有所增加。</p>
</div><h2>Institutional Trading of abrdn Life Sciences Investors</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 的機構交易</h2>
</div><p>A number of institutional investors have recently made changes to their positions in HQL. KPP Advisory Services LLC increased its stake in shares of abrdn Life Sciences Investors by 5.8% during the first quarter. KPP Advisory Services LLC now owns 24,591 shares of the company's stock valued at $400,000 after acquiring an additional 1,354 shares during the period. Geneos Wealth Management Inc. lifted its position in abrdn Life Sciences Investors by 200.1% in the second quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company's stock worth $29,000 after purchasing an additional 1,529 shares during the period. NewEdge Advisors LLC boosted its stake in abrdn Life Sciences Investors by 5.2% during the 2nd quarter. NewEdge Advisors LLC now owns 34,190 shares of the company's stock valued at $438,000 after purchasing an additional 1,690 shares in the last quarter. Uhlmann Price Securities LLC boosted its stake in abrdn Life Sciences Investors by 2.3% during the 1st quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company's stock valued at $1,267,000 after purchasing an additional 1,719 shares in the last quarter. Finally, Blue Bell Private Wealth Management LLC increased its position in shares of abrdn Life Sciences Investors by 2.9% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 64,828 shares of the company's stock valued at $1,005,000 after purchasing an additional 1,800 shares during the period. 32.21% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近對 HQL 的持倉進行了調整。KPP Advisory Services LLC 在第一季度將其在 abrdn Life Sciences Investors 的股份增加了 5.8%。KPP Advisory Services LLC 現在擁有該公司 24,591 股股票，價值 40 萬美元，此前在此期間又購買了 1,354 股。Geneos Wealth Management Inc.在第二季度將其在 abrdn Life Sciences Investors 的持倉增加了 200.1%。Geneos Wealth Management Inc.現在擁有該公司 2,293 股股票，價值 29,000 美元，此前在此期間又購買了 1,529 股。NewEdge Advisors LLC 在第二季度將其在 abrdn Life Sciences Investors 的股份增加了 5.2%。NewEdge Advisors LLC 現在擁有該公司 34,190 股股票，價值 438,000 美元，此前在上個季度又購買了 1,690 股。Uhlmann Price Securities LLC 在第一季度將其在 abrdn Life Sciences Investors 的股份增加了 2.3%。Uhlmann Price Securities LLC 現在擁有該公司 77,857 股股票，價值 1,267,000 美元，此前在上個季度又購買了 1,719 股。最後，Blue Bell Private Wealth Management LLC 在第三季度將其在 abrdn Life Sciences Investors 的持倉增加了 2.9%。Blue Bell Private Wealth Management LLC 現在擁有該公司 64,828 股股票，價值 1,005,000 美元，此前在此期間又購買了 1,800 股。32.21% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>abrdn Life Sciences Investors Company Profile</h2>
<div class="lb-trans"><h2>abrdn Life Sciences Investors 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>abrdn Life Sciences Investors NYSE: HQL is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.</p>
<div class="lb-trans"><p>abrdn Life Sciences Investors NYSE: HQL 是一家封閉式管理投資公司，旨在通過投資生命科學領域實現資本增值。該信託成立於 1994 年，專注於從事生物技術、製藥、醫療設備、診斷及相關領域的公司的股票及相關證券。其封閉式結構使投資組合經理能夠維持穩定的資本池，追求長期投資策略，並在適當時使用槓桿。</p>
</div><p>The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.</p>
<div class="lb-trans"><p>該基金的投資組合涵蓋了公共和私人公司，重點關注推動藥物開發、基因治療、精準醫療和醫療技術創新的企業。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than abrdn Life Sciences Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 abrdn Life Sciences Investors</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in abrdn Life Sciences Investors Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 abrdn Life Sciences Investors 嗎？</h2>
</div><p>Before you consider abrdn Life Sciences Investors, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 abrdn Life Sciences Investors 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and abrdn Life Sciences Investors wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 abrdn Life Sciences Investors 並不在名單上。</p>
</div><p>While abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 abrdn Life Sciences Investors 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

abrdn Life Sciences Investors（NYSE:HQL）創下 52 周新高 - 現在是買入的好時機嗎？